Editas Medicine, Inc. (EDIT): Cash & Equivalents
$146.65M
As of 2025-12-31
$181.81M
As of 2026-06-30
+1.2%
3-year compound annual growth
+1.0%
5-year compound annual growth
+0.2%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $146.65M | +11.5% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $131.54M | +6.4% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $123.65M | -12.6% | 2025-03-05, Balance as of period end |
| 2022-12-31 | $141.52M | -30.5% | 2025-03-05, Balance as of period end |
| 2021-12-31 | $203.52M | +45.7% | 2023-02-22, Balance as of period end |
| 2020-12-31 | $139.68M | -41.4% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $238.18M | +76.7% | 2021-02-26, Balance as of period end |
| 2018-12-31 | $134.78M | -8.1% | 2020-02-26, Balance as of period end |
| 2017-12-31 | $146.63M | -20.9% | 2020-02-26, Balance as of period end |
| 2016-12-31 | $185.32M | +29.4% | 2019-03-01, Balance as of period end |
| 2015-12-31 | $143.18M | n/m | 2018-03-08, Balance as of period end |
| 2014-12-31 | $10.62M | n/a | 2017-03-03, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $146.65M | +11.5% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $65.30M | -8.5% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $20.95M | -50.0% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $357.01M | +196.9% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $36.79M | +38.1% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $74.60M | +34.4% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $217.05M | +289.7% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $110.82M | +29.0% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $14.68M | -25.7% |
Compare EDIT, VYGR, SGMOQ, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗